Dayvigo (Lemborexant) in South Asian Patients: Documented Efficacy Gaps and Pharmacogenomic Considerations
South Asian patients may respond differently to lemborexant (Dayvigo) due to CYP3A4 polymorphisms, body composition differences, and underrepresentation in key trials. This article reviews available ethnicity-stratified data, pharmacogenomic factors, and practical dosing guidance.
Read clinical review